CN102137846A - N-(2-氨基苯基)-4-[n-(吡啶-3-基)甲氧基羰基氨基甲基]苯甲酰胺(ms-275)多晶型物b - Google Patents
N-(2-氨基苯基)-4-[n-(吡啶-3-基)甲氧基羰基氨基甲基]苯甲酰胺(ms-275)多晶型物b Download PDFInfo
- Publication number
- CN102137846A CN102137846A CN2009801340578A CN200980134057A CN102137846A CN 102137846 A CN102137846 A CN 102137846A CN 2009801340578 A CN2009801340578 A CN 2009801340578A CN 200980134057 A CN200980134057 A CN 200980134057A CN 102137846 A CN102137846 A CN 102137846A
- Authority
- CN
- China
- Prior art keywords
- aminophenyl
- pyridin
- amino methyl
- benzamide
- methoxycarbonyl amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *=C(NCc(cc1)ccc1C(Nc(cccc1)c1N)=O)OCc1cccnc1 Chemical compound *=C(NCc(cc1)ccc1C(Nc(cccc1)c1N)=O)OCc1cccnc1 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
多晶型物A | 多晶型物B | 多晶型物C |
160℃±1K | 157℃±1K | 152℃-155℃ |
多晶型物A | 多晶型物B | 多晶型物C |
18.4 | 9.2 | 17.7 |
18.8 | 18.1 | 18.4 |
19.1 | 19.4 | 18.8 |
20.9 | 20.0 | 19.2 |
22.6 | 20.4 | 20.0 |
26.4 | 21.1 | 22.0 |
26.7 | 22.1 | 22.3 |
27.2 | 25.8 | 23.2 |
27.4 | 23.4 |
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9304608P | 2008-08-29 | 2008-08-29 | |
EP08163274.7 | 2008-08-29 | ||
US61/093,046 | 2008-08-29 | ||
EP08163274 | 2008-08-29 | ||
PCT/EP2009/006381 WO2010022988A1 (en) | 2008-08-29 | 2009-08-27 | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102137846A true CN102137846A (zh) | 2011-07-27 |
CN102137846B CN102137846B (zh) | 2014-04-23 |
Family
ID=41133825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980134057.8A Active CN102137846B (zh) | 2008-08-29 | 2009-08-27 | N-(2-氨基苯基)-4-[n-(吡啶-3-基)甲氧基羰基氨基甲基]苯甲酰胺(ms-275)多晶型物b |
Country Status (36)
Country | Link |
---|---|
US (2) | US7973166B2 (zh) |
EP (1) | EP2350005B1 (zh) |
JP (1) | JP4921616B2 (zh) |
KR (1) | KR101073760B1 (zh) |
CN (1) | CN102137846B (zh) |
AR (1) | AR073226A1 (zh) |
AT (1) | ATE538094T1 (zh) |
AU (1) | AU2009286982C1 (zh) |
BR (1) | BRPI0918580B8 (zh) |
CA (1) | CA2735294C (zh) |
CO (1) | CO6351736A2 (zh) |
CR (2) | CR20110107A (zh) |
CY (1) | CY1112645T1 (zh) |
DK (1) | DK2350005T3 (zh) |
DO (1) | DOP2011000064A (zh) |
EA (1) | EA016811B1 (zh) |
EC (1) | ECSP11010849A (zh) |
ES (1) | ES2378640T3 (zh) |
HK (1) | HK1160107A1 (zh) |
HN (1) | HN2011000609A (zh) |
HR (1) | HRP20120183T8 (zh) |
IL (1) | IL211276A (zh) |
MA (1) | MA32610B1 (zh) |
MX (1) | MX2011002248A (zh) |
MY (1) | MY149058A (zh) |
NZ (1) | NZ591387A (zh) |
PE (2) | PE20141062A1 (zh) |
PL (1) | PL2350005T3 (zh) |
PT (1) | PT2350005E (zh) |
RS (1) | RS52164B (zh) |
SI (1) | SI2350005T1 (zh) |
SM (1) | SMT201200026B (zh) |
SV (1) | SV2011003846A (zh) |
TW (1) | TWI427062B (zh) |
WO (1) | WO2010022988A1 (zh) |
ZA (1) | ZA201102285B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019019130A1 (zh) * | 2017-07-28 | 2019-01-31 | 杭州领业医药科技有限公司 | 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2350005T3 (da) | 2008-08-29 | 2012-03-19 | Bayer Pharma AG | N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
FR2977492B1 (fr) * | 2011-07-04 | 2013-07-05 | Servier Lab | Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
EP3168210A1 (en) | 2015-11-13 | 2017-05-17 | Sandoz Ag | Crystalline forms of entinostat |
WO2017216761A1 (en) * | 2016-06-17 | 2017-12-21 | Dr. Reddy's Laboratories Limited | Solid forms of entinostat |
KR20240019100A (ko) | 2021-05-10 | 2024-02-14 | 맥파란 스미스 리미티드 | 엔티노스타트의 신규 형태 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
JP4030683B2 (ja) * | 1998-07-24 | 2008-01-09 | 三井化学株式会社 | ベンズアミド誘導体の合成法 |
US6320078B1 (en) * | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
JP2001064177A (ja) * | 1999-08-16 | 2001-03-13 | Schering Ag | ベンズアミド誘導体を有効成分とする製剤 |
JP4360660B2 (ja) * | 1999-11-09 | 2009-11-11 | 三井化学株式会社 | モノアシルフェニレンジアミン誘導体の精製法 |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
DK2350005T3 (da) | 2008-08-29 | 2012-03-19 | Bayer Pharma AG | N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B |
-
2009
- 2009-08-27 DK DK09778301T patent/DK2350005T3/da active
- 2009-08-27 CN CN200980134057.8A patent/CN102137846B/zh active Active
- 2009-08-27 MY MYPI2011000789A patent/MY149058A/en unknown
- 2009-08-27 PL PL09778301T patent/PL2350005T3/pl unknown
- 2009-08-27 KR KR1020117007131A patent/KR101073760B1/ko active IP Right Review Request
- 2009-08-27 PE PE2014000099A patent/PE20141062A1/es not_active Application Discontinuation
- 2009-08-27 ES ES09778301T patent/ES2378640T3/es active Active
- 2009-08-27 AT AT09778301T patent/ATE538094T1/de active
- 2009-08-27 SI SI200930182T patent/SI2350005T1/sl unknown
- 2009-08-27 AU AU2009286982A patent/AU2009286982C1/en active Active
- 2009-08-27 EA EA201100354A patent/EA016811B1/ru active IP Right Grant
- 2009-08-27 WO PCT/EP2009/006381 patent/WO2010022988A1/en active Application Filing
- 2009-08-27 JP JP2011524272A patent/JP4921616B2/ja active Active
- 2009-08-27 PE PE2011000218A patent/PE20110677A1/es not_active Application Discontinuation
- 2009-08-27 NZ NZ591387A patent/NZ591387A/en unknown
- 2009-08-27 MX MX2011002248A patent/MX2011002248A/es active IP Right Grant
- 2009-08-27 BR BRPI0918580A patent/BRPI0918580B8/pt active IP Right Grant
- 2009-08-27 RS RSP20120083 patent/RS52164B/en unknown
- 2009-08-27 CA CA 2735294 patent/CA2735294C/en active Active
- 2009-08-27 PT PT09778301T patent/PT2350005E/pt unknown
- 2009-08-27 EP EP20090778301 patent/EP2350005B1/en active Active
- 2009-08-28 AR ARP090103317 patent/AR073226A1/es unknown
- 2009-08-28 TW TW098129170A patent/TWI427062B/zh active
- 2009-08-28 US US12/549,458 patent/US7973166B2/en not_active Ceased
-
2011
- 2011-02-17 IL IL211276A patent/IL211276A/en active IP Right Grant
- 2011-02-28 SV SV2011003846A patent/SV2011003846A/es unknown
- 2011-02-28 CR CR20110107A patent/CR20110107A/es unknown
- 2011-02-28 DO DO2011000064A patent/DOP2011000064A/es unknown
- 2011-02-28 EC ECSP11010849 patent/ECSP11010849A/es unknown
- 2011-02-28 CO CO11024240A patent/CO6351736A2/es unknown
- 2011-02-28 HN HN2011000609A patent/HN2011000609A/es unknown
- 2011-03-04 MA MA33670A patent/MA32610B1/fr unknown
- 2011-03-28 ZA ZA2011/02285A patent/ZA201102285B/en unknown
-
2012
- 2012-01-11 HK HK12100290.3A patent/HK1160107A1/zh unknown
- 2012-02-24 HR HRP20120183AT patent/HRP20120183T8/hr unknown
- 2012-03-20 CY CY20121100293T patent/CY1112645T1/el unknown
- 2012-06-01 SM SM201200026T patent/SMT201200026B/it unknown
-
2014
- 2014-03-07 US US14/201,684 patent/USRE45499E1/en active Active
-
2016
- 2016-08-27 CR CR20160465A patent/CR20160465A/es unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019019130A1 (zh) * | 2017-07-28 | 2019-01-31 | 杭州领业医药科技有限公司 | 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物 |
CN110944978A (zh) * | 2017-07-28 | 2020-03-31 | 杭州领业医药科技有限公司 | 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物 |
US11208382B2 (en) | 2017-07-28 | 2021-12-28 | Hangzhou Solipharma Co., Ltd. | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102137846B (zh) | N-(2-氨基苯基)-4-[n-(吡啶-3-基)甲氧基羰基氨基甲基]苯甲酰胺(ms-275)多晶型物b | |
TWI549954B (zh) | 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉鹽 | |
CN102762557B (zh) | 三唑并吡啶 | |
CN103228274A (zh) | 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合 | |
CN103403006B (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪 | |
CN102834100A (zh) | 新型pan-CDK抑制剂用于治疗肿瘤的用途 | |
CN104220075A (zh) | (rs)-s-环丙基-s-(4-{[4-{[(1r,2r)-2-羟基-1-甲基丙基]氧基}-5-(三氟甲基)嘧啶-2-基]氨基}苯基)亚砜亚胺用于治疗特定肿瘤的用途 | |
GB2462893A (en) | Preparation of and compositions comprising N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]-benzamide (MS-275) polymorph B | |
NZ616198B2 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
EP2964259A1 (de) | Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore | |
CN103649087A (zh) | 取代的咪唑并吡啶及其中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1160107 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMA AG Effective date: 20130725 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130725 Address after: German Monheim Applicant after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Berlin Applicant before: Bayer Pharma AG |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110727 Assignee: Eddingpharm Investment Co.,Ltd. Assignor: SYNDAX PHARMACEUTICALS, Inc. Contract record no.: 2013990000643 Denomination of invention: N- (2- amino phenyl) -4-[N- (pyridyl -3- group) methoxy carbonyl amino] [benzamide (MS-275) polymorphs B License type: Exclusive License Record date: 20130930 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1160107 Country of ref document: HK |
|
CP02 | Change in the address of a patent holder |
Address after: 50 Alfred Nobel Street, 40789 Monheim on the Rhine, Germany Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Germany Patentee before: BAYER INTELLECTUAL PROPERTY GmbH |
|
CP02 | Change in the address of a patent holder |